Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair

Rhea-AI Summary

Repligen (NASDAQ: RGEN) announced that Dr. Martin D. Madaus was elected Chair of the Board effective March 13, 2026, as Executive Chair Tony Hunt retires from the Board on that date and will remain as an advisor through March 2027. Dr. Madaus has served as a Repligen director since February 2023 and brings 36 years of industry experience, including five years as Chairman, President and CEO of Millipore and involvement in its 2010 acquisition by Merck KGaA. Dr. Madaus also serves on the boards of Azenta and Hologic and holds a D.V.M. and Ph.D. from universities in Germany.

Positive

• New Chair effective March 13, 2026
• Tony Hunt advisory role through March 2027
• Dr. Madaus 36 years industry experience

Negative

• Executive Chair role vacated on March 13, 2026

Key Figures

Effective date March 13, 2026 Martin D. Madaus becomes Chair of the Board

Advisor term end March 2027 Tony Hunt to remain advisor to Repligen

Industry experience 36 years Dr. Madaus’ total industry experience

Millipore leadership tenure 5 years Time as Chairman, President and CEO of Millipore Corporation

Current price $169.44 Pre-news trading level for RGEN

52-week high $182.52 RGEN trading below its 52-week high

52-week low $102.965 RGEN significantly above its 52-week low

Market cap $9,251,384,598 Equity value prior to the leadership change news

Market Reality Check

$166.42 Last Close

Volume Volume 567,879 is close to the 552,948 20-day average, indicating typical trading interest ahead of the leadership transition. normal

Technical Price $169.44 is trading above the $135.63 200-day moving average, reflecting a pre-existing upward trend into this governance update.

Peers on Argus

RGEN gained 3.1% while several medical instruments peers also traded higher, including MMSI up 4.27% and BLCO up 3.58%, suggesting generally constructive sector tone even though momentum scanners did not flag a coordinated sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 18	Conference appearance	Neutral	+0.5%	J.P. Morgan 2026 Healthcare Conference presentation announcement.
Dec 16	Product launch	Positive	-1.6%	Launch of next-generation chromatography resins for new modalities.
Nov 26	Conference appearance	Neutral	-0.3%	Participation in Evercore healthcare conference with webcast access.
Nov 04	Investor conferences	Neutral	-2.2%	Schedule of multiple November investor conferences with management.
Oct 28	Earnings and guidance	Positive	-5.9%	Q3 2025 beat, raised full-year guidance and strong growth metrics.

Pattern Detected

Recent history shows occasional negative price reactions to positive fundamental news (notably the Q3 2025 earnings beat and product launch), while conference-related headlines have produced relatively muted moves.

Recent Company History

Over the last few months, Repligen has focused on investor outreach and product expansion, with multiple conference appearances and the launch of new chromatography resins in Dec 2025. The Q3 2025 results showed strong revenue growth and raised guidance, yet the stock declined 5.92% the next day, indicating past instances where solid fundamentals did not translate into immediate gains. Against this backdrop, today’s leadership transition announcement follows a period of operational momentum and active capital markets communication.

Market Pulse Summary

This announcement details a planned governance transition, with Dr. Martin D. Madaus becoming Chair on March 13, 2026 and Tony Hunt remaining as advisor through March 2027. The move follows a period of strong reported growth in 2025 and active investor outreach. Investors may monitor how board leadership supports execution of Repligen’s bioprocessing strategy, while keeping an eye on insider trading trends marked as Net Selling over the past 90 days and future financial updates.

Key Terms

nasdaq financial

"Repligen Corporation (NASDAQ:RGEN), a life sciences company"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

board of directors regulatory

"retiring from his role as Executive Chair and member of the Board of Directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

bioprocessing technical

"a life sciences company focused on bioprocessing technology leadership"

Bioprocessing is the set of manufacturing steps that use living cells or biological ingredients to make medicines, vaccines, diagnostics, or other biological products. Think of it as an assembly line where living systems, rather than machines, create the final product; variations in scale, consistency and cost directly affect a product’s ability to reach patients and generate revenue. Investors watch bioprocessing for its impact on production risk, regulatory approval and profit margins.

biopharma technical

"deep expertise and strong leadership in bioprocessing and biopharma"

Biopharma companies discover and develop medicines and treatments derived from biological sources—such as proteins, cells, or genetic material—rather than from purely synthetic chemicals. For investors, biopharma matters because successful products can deliver large, protected revenues but require long, costly development and strict regulatory approval, creating a higher-risk, potentially higher-reward profile; think of them as chefs transforming living ingredients into precision medicines.

AI-generated analysis. Not financial advice.

WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. As previously communicated¹, Tony Hunt is retiring from his role as Executive Chair and member of the Board of Directors effective this March 13th. Mr. Hunt will continue to serve as an advisor to Repligen through March 2027.

“On behalf of Repligen, I want to thank Tony for over a decade of service to the Company, during which he expanded our unique and diversified portfolio of innovative products,” said Olivier Loeillot, Repligen President and CEO. “He left a strong foundation for us to build upon, and with Martin assuming the role of Chair of the Board, we are well-positioned for success. Martin’s deep expertise and strong leadership in bioprocessing and biopharma makes him exceptionally qualified to lead our Board.”

Dr. Martin D. Madaus added, “On behalf of the Board of Directors, our shareholders, employees, and other stakeholders, I want to commend Tony on his impressive tenure at Repligen. I am honored to be elected as Chair of the Repligen Board and look forward to guiding Repligen towards new heights.”

Tony Hunt said, “After more than a decade of leadership, I leave this Company immensely proud of the business we have created together. One that is rooted in clear strategy, disciplined execution and outstanding people. It has been a privilege and an honor to work alongside such a committed team, and I leave knowing the Company is in very capable hands. I am confident that Olivier and Martin will build on the success we have enjoyed and lead Repligen to a new phase of growth.”

Martin D. Madaus, D.V.M., Ph.D., has served as a director of Repligen since February 2023. Dr. Madaus has 36 years of industry experience, including five years as Chairman, President and CEO of Millipore Corporation, where he was integral to the company’s transformation into a life science leader, and its acquisition by Merck KGaA in 2010. Dr. Madaus serves on the boards of Azenta, Inc. and Hologic, Inc. He holds a D.V.M. from the University of Munich in Germany and a Ph.D. from the University of Veterinary Medicine of Hanover in Germany.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.

This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.

Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com

________________________
¹ Repligen June 14, 2024 8-K

FAQ

When does Repligen (RGEN) leadership change take effect?

Dr. Martin D. Madaus becomes Chair effective March 13, 2026.

What happens to Tony Hunt after his Repligen (RGEN) retirement?

Tony Hunt retires from the Board on March 13, 2026 and will serve as an advisor through March 2027.

How long has Dr. Martin D. Madaus served on Repligen (RGEN) board?

Dr. Madaus has served as a Repligen director since February 2023.

What is Dr. Martin D. Madaus's industry background relevant to RGEN?

He has 36 years of industry experience and served five years as Chairman, President and CEO of Millipore.

Does Dr. Madaus hold other board positions while chairing Repligen (RGEN)?

Yes; he serves on the boards of Azenta and Hologic.